Active work is underway to develop vaccines against coronavirus

December 03 , 2020

 

As of December 2, 2020, 41 coronavirus vaccines are in the first phase of research, 17 vaccines are in the second phase and 13 are in the third phase. 7 vaccines are allowed for limited use. (https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html)

The UK government allowed the use of Pfizer / BioNTech vaccines on 2 December. The vaccine will be available in the UK next week. FDA approval . is currently pending in the United States.(https://www.gov.uk/government/news/uk-authorises-pfizer-biontech-covid-19-vaccine)

In July, the US government contracted $ 1.9 million for 100 million doses, with the possibility of purchasing an additional 500 million doses. Meanwhile, Japan has reached an agreement for 120 million doses, and the European Union has agreed to purchase 200 million doses. Pfizer and BioNTech are expanding production of more than 1.3 billion to create a vaccine worldwide by the end of 2021.

Pfizer / BioNTech requires deep freezing (down to -70 ° C) for storage. In addition, as with most vaccines currently being tested, the vaccines need to be re-injected every three weeks. All this can create additional logistical problems in the spread of the vaccine.

# covid19 #coronavirus #covid #coronavirus #otipharm_news

We help to prepare all the necessary documents for the registration of medicines, medical devices, dietary supplements, and cosmetic products

DOWNLOAD PDF